Pricing Log in Create free account
Saturday 17 October 2026 Export MGTX’s income statement to Excel — free account

MeiraGTx Holdings PLC

MGTX Healthcare Biotechnology

MeiraGTx Holdings PLC’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 144.6% from fiscal 2024. In the quarter to June 2026, revenue grew 8,608.6%, EPS grew 466.7%, free cash flow grew 13.1% and total debt rose 28.6%, each against the same quarter a year earlier.

9.28 0.61 −6.17%
Market cap
$949.9M
P/E
12.2×
Fwd P/E
−5.6×
Dividend yield
—
F-score
5/9
Altman Z
−4.39
Beneish M
−3.01
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 4.12
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — 1 2 1 — 2 1 — 1
Insider Ownership 19.46%

Capital & Financial Ratios $m

Market Cap 949.86
Revenue 397.50
Net Income 78.93
Free Cash Flow 10.12
Net Debt (43.08)
Current Ratio 3.76 (at or above 1.5: strong)
Debt/Equity 0.46 (at or below 0.5: strong)
P/E ratio 12.21
Fwd P/E (5.62) (negative: loss-making)
P/S ratio 2.13
P/B ratio 3.93
Past 5Y EPS Growth —
This Y EPS Growth 121.13% (at or above 15%: strong)
Next Y EPS Growth (683.81%) (below 0%: weak)
Next Y revenue growth 314.17% (at or above 10%: strong)
Next 5Y EPS Growth 5.92%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.0×, against a ten-year median of 19.9×; over the ten years it ranged from 2.0× in 2026 to 65.9× in 2023.
P/S against its own 10 years 0.06%
10-year low 10-year high
P/B against its own 10 years 72.34%
10-year low 10-year high
EV/Sales against its own 10 years 0.06%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 130 104 66 143
Receivables 23 10 18 44
Inventory — 0 — —
Other 1 3 2 27
160 124 92 218
2023 2024 2025 Q'26
Payables 16 24 10 12
ST’ Debt — — — —
Other 1 1 50 15
67 61 123 58

Compound Annual Growth %

10y 5y 3y
Sales — 39.22% 72.27%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 0 321 — — —
’25 2 4 0 75 81
’24 1 0 11 21 33
’23 3 4 5 2 14
’22 6 11 5 (5) 16
’21 5 5 7 21 38
’20 4 2 5 4 16
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 18 (39) — — —
’25 (37) (44) (12) 47 (46)
’24 (37) (19) (25) (23) (104)
’23 (37) (29) (24) (15) (105)
’22 (8) (28) (21) (16) (73)
’21 9 (21) (17) 19 (11)
’20 (12) (13) (9) (30) (64)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 16 (39) — — —
’25 (39) (45) (13) 46 (50)
’24 (38) (21) (26) (24) (109)
’23 (46) (34) (28) (18) (126)
’22 (21) (42) (31) (25) (118)
’21 5 (27) (29) (6) (57)
’20 (16) (16) (15) (38) (87)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.57) 1.71 — — —
’25 (0.51) (0.48) (0.62) 0.19 (1.42)
’24 (0.32) (0.76) (0.55) (0.50) (2.12)
’23 (0.62) (0.53) (0.74) 0.42 (1.49)
’22 (0.70) (0.76) (0.83) (0.58) (2.87)
’21 (0.54) (0.46) (0.59) (0.22) (1.80)
’20 (0.43) (0.69) (0.17) (0.25) (1.54)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — 7.98 9.10 8.82 11.60 5.70 3.49 3.85 4.55

Analyst estimates 2026–2028

Powerpack
High — — 15.49 30.23 21.77 24.90 24.33 8.77 7.57 9.73
People
People Employees — 59 68 157 219 296 358 425 381 403
Revenue/emp, $m — 0.00 0.00 0.08 0.07 0.13 0.04 0.03 0.09 0.20
Income, $m
Income, $m Revenue — — — 13 16 38 16 14 33 81
Gross margin, % 0.00 0.00 0.00 100.00 100.00 100.00 100.00 100.00 28.51 94.05
EBT (20) (31) (83) (55) (58) (80) (130) (84) (148) (114)
EBT margin, % 0.00 0.00 0.00 (411.87) (372.63) (211.03) (814.16) (599.46) (444.10) (140.31)
Net income (20) (31) (83) (55) (58) (80) (130) (84) (148) (114)
Depreciation 0 1 2 2 4 8 9 15 14 14
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.40 0.41 0.85 0.35 0.25 0.48 1.01
Earnings (2.47) (3.62) (4.47) (1.65) (1.54) (1.80) (2.87) (1.49) (2.12) (1.42)
Cash flow (1.79) (2.11) (3.11) 0.60 (1.70) (0.24) (1.62) (1.87) (1.50) (0.58)
Capex (0.32) (1.23) (0.59) (0.27) (0.61) (1.05) (1.00) (0.36) (0.07) (0.05)
Free cash flow (2.12) (3.34) (3.70) 0.33 (2.31) (1.29) (2.61) (2.22) (1.57) (0.62)
Book value (2.14) (5.53) 4.28 5.75 6.32 4.20 2.61 2.45 0.97 (0.07)
Shares, m 8 9 19 33 38 44 45 56 70 80
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — — 49.95 36.70 27.79 18.39 29.54 12.78 7.86
P/B — — — 3.48 2.39 5.65 2.49 3.00 6.27 0.00
EV/Sales — — — 34.47 24.50 24.68 16.68 26.36 11.86 7.66
EV/FCF — — — 41.41 (4.49) (16.36) (2.25) (2.94) (3.61) (12.45)
Cash, $m
Cash, $m Operating cash flow (14) (18) (59) 20 (64) (11) (73) (105) (104) (46)
Capex (3) (11) (11) (9) (23) (46) (45) (20) (5) (4)
Free cash flow (17) (29) (70) 11 (87) (57) (118) (126) (109) (50)
Balance, $m
Balance, $m Working capital 13 (10) 59 220 218 115 72 93 63 (31)
Total debt 0 0 0 22 20 20 88 85 73 50
Net debt (17) (9) (68) (206) (190) (117) (27) (44) (30) (16)
Shareholders’ equity (17) (47) 81 191 239 185 118 138 68 (6)
Returns, %
Returns, % ROA (80.87) (131.60) (137.96) (26.02) (16.87) (23.27) (40.61) (26.06) (49.55) (44.42)
ROIC 0.00 0.00 (375.89) 0.00 (80.27) (66.82) (80.28) (91.44) (274.50) 0.00
ROE 60.68 98.76 (502.59) (40.28) (27.01) (37.53) (85.52) (65.67) (143.48) (368.19)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

MeiraGTx Holdings PLC vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MNKD MannKind Corporation $1.0B — (loss-making) — (loss-making) +42.92% (above 0%: growing) n/m −399.41% (below 0%: shrinking) 72.99% (0.32%) Compare
SVRA Savara Inc. $973.9M — (loss-making) — (loss-making) — n/m −14.05% (below 0%: shrinking) 0.00% 0.00% Compare
MGTX MeiraGTx Holdings PLC $949.9M 12.2× — (loss-making) +8,608.59% (above 0%: growing) n/m +13.06% (above 0%: growing) 97.77% 76.04%
CGEM Cullinan Therapeutics, Inc. $901.0M — (loss-making) 4.8× — n/m +33.66% (above 0%: growing) 100.00% 0.00% Compare
AKTS Aktis Oncology, Inc. $890.5M — (loss-making) — (loss-making) — n/m −12.77% (below 0%: shrinking) 100.00% (853.99%) Compare
ANRO Alto Neuroscience, Inc. $887.7M — (loss-making) — — n/m −43.41% (below 0%: shrinking) — 0.00% Compare
RIGL Rigel Pharmaceuticals, Inc. $882.6M 2.6× 7.9× −22.60% (below 0%: shrinking) −72.07% (below 0%: shrinking) −229.99% (below 0%: shrinking) 89.17% 29.95% Compare
JBIO Jade Biosciences, Inc. $875.1M — (loss-making) — — n/m −115.11% (below 0%: shrinking) 0.00% 0.00% Compare
MLTX MoonLake Immunotherapeutics $873.2M — (loss-making) — — n/m −1.89% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $889.1M — — — — −28.73% 72.99% 0.00%

All 614 Biotechnology stocks →

MeiraGTx Holdings PLC (MGTX) key facts

  • Strength: MeiraGTx Holdings PLC’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 144.6% from fiscal 2024.
  • MeiraGTx Holdings PLC (MGTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, MGTX traded at $9.28, a market capitalization of $949.9 million.
  • Return on equity was −368.2% and debt-to-equity 0.46.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −4.39 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

MeiraGTx Holdings PLC (MGTX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/MGTX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com